Researchers have launched a Phase-1 Ebola vaccine trial in the UK and a clinical trial for two experimental treatments in the Democratic Republic of Congo.
These efforts aim to develop medical countermeasures against an Ebola outbreak that is currently widening in eastern Congo. The dual approach of testing both a preventative vaccine and active treatments represents a critical step in reducing mortality rates during active outbreaks.
In the Democratic Republic of Congo, the PARTNERS trial began in the first week of July [4] in the Ituri Province, specifically within Bunia and surrounding areas. This trial is testing two experimental treatments [3] to determine their efficacy in treating patients. The World Health Organization and the Institut National de Santé said the trial enrollment started July 2, 2026 [5].
Simultaneously, the University of Oxford is moving forward with a new vaccine. The Phase-1 trial in the United Kingdom is seeking 50 healthy adult volunteers [1] to test the safety and immune response of the candidate. This project is part of a broader global effort, as there are currently four Ebola vaccines under development [2].
The trials involve a collaboration between the University of Oxford, the World Health Organization, and various partner institutions. These organizations are working to address the specific challenges of the Bundibugyo virus and other Ebola strains affecting the region.
Health workers in the DRC are administering the experimental therapies as residents in eastern Congo look for hope amid the widening outbreak. The coordination between UK-based research and field implementation in Africa is intended to accelerate the timeline for approved medical interventions.
“The PARTNERS trial is testing two experimental treatments to determine their efficacy in treating patients.”
The simultaneous launch of a Phase-1 vaccine trial and a treatment trial indicates a shift toward a multi-layered defense strategy against Ebola. By pursuing both prevention and cure, health organizations are attempting to create a sustainable infrastructure to contain outbreaks in high-risk zones like the DRC, reducing the reliance on reactive measures once a virus has already spread.
